CY1123398T1 - Συνθεση συνδυασμου - Google Patents

Συνθεση συνδυασμου

Info

Publication number
CY1123398T1
CY1123398T1 CY20191100766T CY191100766T CY1123398T1 CY 1123398 T1 CY1123398 T1 CY 1123398T1 CY 20191100766 T CY20191100766 T CY 20191100766T CY 191100766 T CY191100766 T CY 191100766T CY 1123398 T1 CY1123398 T1 CY 1123398T1
Authority
CY
Cyprus
Prior art keywords
combination composition
paracetamol
ibuprofen
composition
approximately
Prior art date
Application number
CY20191100766T
Other languages
Greek (el)
English (en)
Inventor
Hartley Campbell Atkinson
Original Assignee
Aft Pharmaceuticals Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46024668&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1123398(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aft Pharmaceuticals Limited filed Critical Aft Pharmaceuticals Limited
Publication of CY1123398T1 publication Critical patent/CY1123398T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
CY20191100766T 2010-11-04 2019-07-18 Συνθεση συνδυασμου CY1123398T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NZ58901110 2010-11-04
PCT/NZ2011/000226 WO2012060719A1 (en) 2010-11-04 2011-10-26 A combination composition

Publications (1)

Publication Number Publication Date
CY1123398T1 true CY1123398T1 (el) 2021-10-29

Family

ID=46024668

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20191100766T CY1123398T1 (el) 2010-11-04 2019-07-18 Συνθεση συνδυασμου

Country Status (28)

Country Link
US (6) US20130225685A1 (enExample)
EP (1) EP2635269B1 (enExample)
JP (2) JP2013541583A (enExample)
KR (1) KR101900520B1 (enExample)
CN (2) CN107519159A (enExample)
AU (1) AU2011324137B2 (enExample)
BR (1) BR112013010829B8 (enExample)
CA (1) CA2814057C (enExample)
CL (1) CL2013001250A1 (enExample)
CO (1) CO6771406A2 (enExample)
CY (1) CY1123398T1 (enExample)
DK (1) DK2635269T3 (enExample)
ES (1) ES2742373T3 (enExample)
HR (1) HRP20191489T1 (enExample)
HU (1) HUE045442T2 (enExample)
LT (1) LT2635269T (enExample)
MX (2) MX367209B (enExample)
MY (1) MY160572A (enExample)
NZ (1) NZ609727A (enExample)
PH (2) PH12013500689A1 (enExample)
PL (1) PL2635269T3 (enExample)
PT (1) PT2635269T (enExample)
RS (1) RS59258B1 (enExample)
RU (2) RU2707089C2 (enExample)
SG (1) SG189319A1 (enExample)
SI (1) SI2635269T1 (enExample)
SM (1) SMT201900481T1 (enExample)
WO (1) WO2012060719A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2742373T3 (es) 2010-11-04 2020-02-14 Aft Pharmaceuticals Ltd Una composición de combinación
US9072710B2 (en) 2012-03-16 2015-07-07 Cumberland Pharmaceuticals Inc. Injectable ibuprofen formulation
WO2016008546A1 (en) 2014-07-18 2016-01-21 Everbright Pharmaceuticals S.A.R.L. Aqueous formulation comprising paracetamol and ibuprofen
CN106999454A (zh) * 2014-10-06 2017-08-01 坎伯兰医药品股份有限公司 共同施用静脉内布洛芬和对乙酰氨基酚以治疗疼痛
WO2018192664A1 (en) 2017-04-20 2018-10-25 Hyloris Developments Sa METHOD FOR PREPARING A COMPOSITION WITH A LOW DISSOLVED OXYGEN CONTENT, COMPRISING ACETAMINOPHEN, AND OPTIONALLY ONE OR MORE NSAIDs, AND A COMPOSITION OBTAINED THEREOF
EP4480495A3 (en) * 2017-07-10 2025-06-18 Gel Cap Technologies, LLC Dual release dosage form capsule and methods, devices and systems for making same
US11197830B2 (en) 2019-02-27 2021-12-14 Aft Pharmaceuticals Limited Pharmaceutical composition containing acetaminophen and ibuprofen
US11568752B2 (en) * 2020-01-28 2023-01-31 David Clark Company Incorporated Gateway retrieval alert device for aircraft pushback operations
WO2023281089A2 (en) 2021-07-08 2023-01-12 Krka, D.D., Novo Mesto Pharmaceutical composition comprising naproxen and paracetamol
GR1010769B (el) * 2023-07-27 2024-09-18 Ιουλια Κλεωνος Τσετη Υδατικο διαλυμα ιβουπροφαινης για χρηση σε ενδοφλεβια χορηγηση
IL324832A (en) 2023-06-02 2026-01-01 Ioulia Tseti Pharmaceutical composition comprising ibuprofen
GR1010809B (el) * 2023-09-13 2024-10-25 Ιουλια Τσετη Υδατικο διαλυμα ιβουπροφαινης παρακεταμολης για χρηση σε ενδοφλεβια χορηγηση

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997020551A1 (en) * 1995-12-05 1997-06-12 Adcock Ingram Limited Pharmaceutical composition comprising a skeletal muscle relaxant, a non-steroidal antiinflammatory agent and an analgesic
JP5185488B2 (ja) * 2001-11-02 2013-04-17 カンバーランド ファーマシューティカルズ,インコーポレーテッド 2−(4−イソブチルフェニル)プロピオン酸の医薬組成物
KR101113005B1 (ko) * 2003-03-21 2012-02-24 맥네일-피피씨, 인코포레이티드 비-스테로이드계 항염증성 약물 투여법
BRPI0512756A (pt) * 2004-07-07 2008-04-08 Aft Pharmaceuticals Ltd composição farmacêutica de combinação para o tratamento de dor, método de controle de dor, uso de uma composição e embalagem farmacêutica incluindo comprimidos ou cápsulas
KR20060072839A (ko) * 2004-12-23 2006-06-28 김경태 아세트아미노펜과 이부프로펜을 이용하여 통증조절과 해열작용을 하는 주사제
US7934627B2 (en) * 2005-10-13 2011-05-03 Alcoa Inc. Apparatus and method for high pressure extrusion with molten aluminum
ES2651444T3 (es) * 2006-10-20 2018-01-26 Johnson & Johnson Consumer Inc. Combinación de acetaminofeno con ibuprofeno para el tratamiento del dolor
WO2008079818A2 (en) * 2006-12-21 2008-07-03 Soluprin Pharmaceuticals, Inc. Intravenous administration of water soluble analgesic formulations
US20090264530A1 (en) * 2008-04-16 2009-10-22 Nickell Robert P Combined nsaid and acetaminophen formulation and method
TR201906742T4 (tr) * 2008-10-14 2019-05-21 Aft Pharmaceuticals Ltd Tıbbi bir ürün ve tedavi.
AU2010224063B2 (en) * 2009-03-12 2015-04-16 Cumberland Pharmaceuticals Inc Administration of intravenous ibuprofen
NZ604009A (en) * 2010-07-07 2015-03-27 Aft Pharmaceuticals Ltd A combination composition comprising ibuprofen and paracetamol
ES2742373T3 (es) 2010-11-04 2020-02-14 Aft Pharmaceuticals Ltd Una composición de combinación
CN106999454A (zh) * 2014-10-06 2017-08-01 坎伯兰医药品股份有限公司 共同施用静脉内布洛芬和对乙酰氨基酚以治疗疼痛

Also Published As

Publication number Publication date
US20160235695A1 (en) 2016-08-18
LT2635269T (lt) 2019-09-10
PH12013500689A1 (en) 2013-05-27
KR101900520B1 (ko) 2018-09-19
US11896567B2 (en) 2024-02-13
PT2635269T (pt) 2019-09-04
CA2814057A1 (en) 2012-05-10
MX2013005113A (es) 2013-06-03
EP2635269B1 (en) 2019-05-22
HUE045442T2 (hu) 2019-12-30
US20250134839A1 (en) 2025-05-01
MX367209B (es) 2019-07-22
JP6353577B2 (ja) 2018-07-04
PH12021550804A1 (en) 2022-02-14
ES2742373T3 (es) 2020-02-14
SMT201900481T1 (it) 2019-11-13
BR112013010829A2 (pt) 2016-08-16
US20190029982A1 (en) 2019-01-31
RU2707089C2 (ru) 2019-11-22
AU2011324137A1 (en) 2013-05-02
US20240207210A1 (en) 2024-06-27
RU2015103107A (ru) 2015-06-20
CN107519159A (zh) 2017-12-29
US11446266B2 (en) 2022-09-20
PL2635269T3 (pl) 2019-11-29
RU2013123646A (ru) 2014-12-10
HRP20191489T1 (hr) 2019-11-15
BR112013010829B1 (pt) 2021-12-21
CL2013001250A1 (es) 2013-08-30
EP2635269A4 (en) 2014-09-17
RS59258B1 (sr) 2019-10-31
US20130225685A1 (en) 2013-08-29
JP2017132791A (ja) 2017-08-03
KR20140025314A (ko) 2014-03-04
AU2011324137B2 (en) 2015-05-07
CA2814057C (en) 2022-02-01
DK2635269T3 (da) 2019-08-26
NZ609727A (en) 2015-07-31
US12220392B2 (en) 2025-02-11
JP2013541583A (ja) 2013-11-14
SI2635269T1 (sl) 2019-10-30
CO6771406A2 (es) 2013-10-15
WO2012060719A1 (en) 2012-05-10
SG189319A1 (en) 2013-05-31
CN103298464A (zh) 2013-09-11
EP2635269A1 (en) 2013-09-11
US20230000805A1 (en) 2023-01-05
RU2015103107A3 (enExample) 2018-08-20
MY160572A (en) 2017-03-15
BR112013010829B8 (pt) 2022-01-04

Similar Documents

Publication Publication Date Title
PH12021550804A1 (en) A combination composition
CY1116727T1 (el) Θεραπεια πολλαπλης σκληρυνσης me laquinimod
EA201290833A1 (ru) Применение амисульприда в качестве противорвотного средства
CY1121735T1 (el) 7-benzyλ-10-(2-meθyλobenzyλ)-2,6,7,8,9,10-eξaϋδpoϊmiδazo[1,2-α]πυριδο[4,3-d]πυριμιδιν-5(3η)-ονη για χρηση στην αγωγη του καρκινου
CY1122466T1 (el) Σκευασμα αντισωματος αντι il-17ra και θεραπευτικα σχηματα για την αγωγη της ψωριασης
CY1121646T1 (el) Παραγωγα μορφινανης για την αγωγη υπερβολικης δοσης ναρκωτικων
MX2013007189A (es) Metodos y composiciones adecuados para manejar glucosa en sangre en animales.
CY1121065T1 (el) Αναστολεις ιβατ για την αγωγη ηπατικων νοσων
CY1122899T1 (el) Υδατικη συσταση περιλαμβανουσα παρακεταμολη και ιβουπροφαινη
BR112012016853A2 (pt) "composições farmacêuticas para administração oral de peptídeos de insulina".
CY1118680T1 (el) Φαρμακευτικη συνθεση
AR092177A1 (es) Metodos para tratar o prevenir asma administrando un antagonista de il-4r
CY1114960T1 (el) Συνθεσεις που περιλαμβανουν τραμαδολη και σελεκοξιμπη στην θεραπεια πονου
CY1114988T1 (el) Βενζοδιαζεπινη αναστολεας bromodomain
ATE534378T1 (de) Titrierung von tapentadol
AR089862A1 (es) USO DE LAQUINIMOD PARA EL TRATAMIENTO DE PACIENTES CON ENFERMEDAD DE CROHN EN QUIENES FRACASO UNA TERAPIA ANTI-FACTOR DE NECROSIS TUMORAL a (ANTI-TNFa) DE PRIMERA LINEA
MA34019B1 (fr) Aryltriazolone liée à un bis-aryle et son utilisation
PH12014500386A1 (en) Combination treatment for hepatitis c
BR112013029256A8 (pt) combinação farmacêutica para uso no tratamento de pacientes com diabetes tipo 2
CY1121628T1 (el) 7-βενζυλ-4-(2-μεθυλοβενζυλ)-2,4,6,7,8,9-εξαϋδροϊμιδαζο[1,2-α]πυριδο[3,4-ε]πυριμιδιν-5(1η)-ονη, αλατα αυτης και μεθοδοι χρησης
AR075982A1 (es) Terapia de combinacion de un anticuerpo afucosilado y una o mas de las citoquinas seleccionadas de gm- csf humano, m -csf humano y/o il-3 humano y composicion
AR082312A1 (es) Una composicion farmaceutica de combinacion para tratar diabetes y desordenes metabolicos
CY1122198T1 (el) Ιατρικο προϊον και θεραπεια
PA8784901A1 (es) Utilizacion de un antagonista par1 en el tratamiento de la fibrilacion atrial
CY1118967T1 (el) Φαρμακευτικες συνθεσεις υψηλης δοσης βιοτινης